YR0132
Human VEGFR2 Monoclonal Antibody
Größe
£355.00
- SKU:
- YR0132
- Zusätzliche Namen:
- CD309|FLK1|KDR|VEGFR|VEGFR2
- Anwendung:
- ELISA, FuncS, Neutralisation
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Abclonal
- Immunogen:
- Human VEGFR2
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P35968
- Synonyme:
- CD309;Fetal liver kinase 1;fetal liver kinase-1;FLK1;Kinase insert domain receptor;kinase insert domain receptor (a type III receptor tyrosine kinase);protein-tyrosine kinase receptor Flk-1;soluble VEGFR2;tyrosine kinase growth factor receptor;vascular endothelial growth factor receptor 2;VEGFR;VEGFR2
- Weitere Details:
- Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.
- Versandbedingungen:
- Blue Ice